Topic Highlight
Copyright ©2014 Baishideng Publishing Group Inc.
World J Clin Oncol. Oct 10, 2014; 5(4): 633-645
Published online Oct 10, 2014. doi: 10.5306/wjco.v5.i4.633
Table 1 Important randomised trials of adjuvant treatments for non-small cell lung cancer
Ref.SizeStage1Chemotherapy regimenOSDFS
IALT[14]1867I-IIIPragmatic study of 3-4 cycles of cisplatin (80-100 mg/m2 on D1) with either: vindesine 3 mg/m2 weekly; vinblastine 4 mg/m2 weekly; vinorelbine 30 mg/m2 weekly; etoposide 100 mg/m2 D1-34.1% absolute benefit at 5 yr (HR, 0.86; P < 0.03)5.1% absolute benefit at 5 yr (HR, 0.83; P < 0.003)
NCIC JBR.10[16]482Ib-II4 cycles of: cisplatin 50 mg/m2 D1 + 8; vinorelbine 25 mg/m2 D1, 8, 15, 22 in a 4-wk cycle15% absolute benefit at 5 yr (P = 0.04)12% absolute benefit at 5 yr (P = 0.08)
ANITA[18]840Stage Ib-IIIa4 cycles of: cisplatin 100 mg/m2 D1; vinorelbine 30 mg/m2 D1, 8, 15, 22 in a 4-wk cycle8.6% absolute benefit at 5 yr (P = 0.17 for HR)8.7% absolute benefit at 5 yr (P = 0.002 for HR)
JLCRG[24]999IDaily UFT as tegafur 250 mg/m2 per day plus uracil, for 2 yr3% absolute benefit at 5 yr (P = 0.04)NR
NCIC BR19[30]1242Ib-IIIaGefitinib 250 mg daily for 2 yrHR, 1.24 (P = 0.14)HR, 1.22 (P = 0.15)
CALGB 9633[16]344Ib4 cycles of carboplatin AUC 6 plus paclitaxel 200 mg/m2, every 3 wkHR, 0.83 (P = 0.12)HR, 0.80 (P = 0.065)
Table 2 Incidence of treatment-related World Health Organization grade 3-4 toxicity from adjuvant cisplatin and vinorelbine
TrialJBR.10 (%)[16]ANITA (%)[18]
Anaemia147
Thrombocytopenia31
Neutropenia8573
Febrile neutropenia97
Infection111
Nausea/vomiting2710-171
Diarrhoea2< 1
Constipation53
Anorexia1510
Asthenia/fatigue2815
Peripheral neuropathy33-72
Creatinine elevation(NR)3< 1
Treatment-related mortality40.82